Nivolumab plus cabozantinib in metastatic renal cell carcinoma: real-world evidence from the international ARON-1 study.

Bourlon MT, Galli L, Grande E, Park SH, Melichar B, Schieber TJ, Juan-Fita MJ, Ürün Y, Molina-Cerrillo J, Alonso-Gordoa T, De Giorgi U, Kucharz J, Pérez Calabuig E, Conteduca V, Taha T, Rescigno P, Abu-Sini H, Spinelli GP, Manneh Kopp R, Salfi A, Bhuva D, Valdez-Sandoval P, Mendez-Bribiesca S, Fiala O, Buti S, Marques Monteiro FS, Bamias A, Ghosn M, Massari F, Ansari J, Santoni M

Open source

DOI: 10.3389/fonc.2025.1605282
Published: 2025
Container: Frontiers in oncology
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.3389/fonc.2025.1605282,
  title = {Nivolumab plus cabozantinib in metastatic renal cell carcinoma: real-world evidence from the international ARON-1 study.},
  author = {Bourlon MT and Galli L and Grande E and Park SH and Melichar B and Schieber TJ and Juan-Fita MJ and Ürün Y and Molina-Cerrillo J and Alonso-Gordoa T and De Giorgi U and Kucharz J and Pérez Calabuig E and Conteduca V and Taha T and Rescigno P and Abu-Sini H and Spinelli GP and Manneh Kopp R and Salfi A and Bhuva D and Valdez-Sandoval P and Mendez-Bribiesca S and Fiala O and Buti S and Marques Monteiro FS and Bamias A and Ghosn M and Massari F and Ansari J and Santoni M},
  year = {2025},
  journal = {Frontiers in oncology},
  doi = {10.3389/fonc.2025.1605282},
  url = {https://doi.org/10.3389/fonc.2025.1605282}
}

RIS

TY  - JOUR
TI  - Nivolumab plus cabozantinib in metastatic renal cell carcinoma: real-world evidence from the international ARON-1 study.
AU  - Bourlon MT
AU  - Galli L
AU  - Grande E
AU  - Park SH
AU  - Melichar B
AU  - Schieber TJ
AU  - Juan-Fita MJ
AU  - Ürün Y
AU  - Molina-Cerrillo J
AU  - Alonso-Gordoa T
AU  - De Giorgi U
AU  - Kucharz J
AU  - Pérez Calabuig E
AU  - Conteduca V
AU  - Taha T
AU  - Rescigno P
AU  - Abu-Sini H
AU  - Spinelli GP
AU  - Manneh Kopp R
AU  - Salfi A
AU  - Bhuva D
AU  - Valdez-Sandoval P
AU  - Mendez-Bribiesca S
AU  - Fiala O
AU  - Buti S
AU  - Marques Monteiro FS
AU  - Bamias A
AU  - Ghosn M
AU  - Massari F
AU  - Ansari J
AU  - Santoni M
PY  - 2025
JO  - Frontiers in oncology
DO  - 10.3389/fonc.2025.1605282
UR  - https://doi.org/10.3389/fonc.2025.1605282
ER  -

APA

MT, B., L, G., E, G., SH, P., B, M., TJ, S., MJ, J., Y, Ü., J, M., T, A., U, D. G., J, K., E, P. C., V, C., T, T., P, R., H, A., GP, S., R, M. K., A, S., D, B., P, V., S, M., O, F., S, B., FS, M. M., A, B., M, G., F, M., J, A., & M, S. (2025). Nivolumab plus cabozantinib in metastatic renal cell carcinoma: real-world evidence from the international ARON-1 study.. Frontiers in oncology. https://doi.org/10.3389/fonc.2025.1605282

Source records

pubmed · retrieved 2026-09-26T22:53:57.925Z